EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Therapeutic Advances in Diabetic Kidney Disease

Panagiotis I Georgianos, Vasilios Vaios, Theodoros Eleftheriadis iD, Evangelos Papachristou, Vassilios Liakopoulos iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24032803 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Panagiotis I Georgianos und 4 weiteren Autor:innen. Beteiligte Einrichtung: 2nd Department of Nephrology, AHEPA Hospital, Aristotle University of Thessaloniki, GR54636 Thessaloniki, Greece. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although sodium glucose co-transporter type 2 (SGLT-2) inhibitors were initially introduced as glucose-lowering medications, it was later discovered that cardiorenal protection is the most important treatment effect of these agents. A triad of landmark trials consistently showed the benefits of SGLT-2 inhibitors on kidney and cardiovascular outcomes in patients with chronic kidney disease (CKD), irrespective of the presence or absence of Type 2 diabetes (T2D). Furthermore, finerenone is a novel, selective, nonsteroidal mineralocorticoid receptor antagonist (MRA) that safely and effectively improved cardiorenal outcomes in a large Phase 3 clinical trial program that included >13,000 patients with T2D and a wide spectrum of CKD. These two drug categories have shared and distinct mechanisms of action, generating the hypothesis that an overadditive cardiorenal benefit with their combined use may be biologically plausible. In this article, we describe the mechanism of action, and we provide an overview of the evidence for cardiorenal protection with SGLT-2 inhibitors and the nonsteroidal MRA finerenone in patients with CKD associated with T2D.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic NephropathiesDiabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsRenal Insufficiency, ChronicHumansGlucose

Stichwörter der Autor:innen

SGLT-2 inhibitorsType 2 diabetescardiorenal protectionchronic kidney diseasefinerenone

Substanzen

Sodium-Glucose Transporter 2 InhibitorsGlucose

Autor:innen und Institutionen

  • 2nd Department of Nephrology, AHEPA Hospital, Aristotle University of Thessaloniki, GR54636 Thessaloniki, Greece.
  • Department of Nephrology, School of Medicine, University of Thessaly, GR41110 Larissa, Greece.
  • Department of Nephrology and Kidney Transplantation, University Hospital of Patras, GR26504 Patras, Greece.

ORCID-Profile: Theodoros Eleftheriadis, Vassilios Liakopoulos

Zitieren

APA

Georgianos, P. I., Vaios, V., Eleftheriadis, T., Papachristou, E., & Liakopoulos, V. (2023). Therapeutic Advances in Diabetic Kidney Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24032803

Vancouver

Georgianos PI, Vaios V, Eleftheriadis T, Papachristou E, Liakopoulos V. Therapeutic Advances in Diabetic Kidney Disease. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24032803

BibTeX
@article{Georgianos2023,
  author = {Georgianos, Panagiotis I and Vaios, Vasilios and Eleftheriadis, Theodoros and Papachristou, Evangelos and Liakopoulos, Vassilios},
  title = {Therapeutic Advances in Diabetic Kidney Disease},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24032803}
}
Kostenlos starten →